







an Open Access Journal by MDPI

Immunotherapy in Thoracic Oncology: Incredible Progress and Remaining Challenges

Guest Editors:

Dr. Dwight H. Owen

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center – James Comprehensive Cancer Center, 1800 Cannon Drive, Suite 1240, Columbus, OH 43210, USA

Dr. Greg Durm

Division of Hematology/Oncology, Department of Medicine, IU School of Medicine, Indianapolis, IN, USA

Deadline for manuscript submissions:

closed (1 December 2022)

Message from the Guest Editors

This Special Issue will focus on the significant progress in the treatment of thoracic cancers in recent years, including reviews of the new standard of care for lung cancer as well as rarer cancers such as mesothelioma and thymic neoplasms. Just as important are the challenges that remain to be overcome. In this issue, we will focus on treatment of patients with NSCLC in second line and beyond, use of ICI in patients with earlier-stage NSCLC, the unique pharmacology of ICI, the role of ICI in elderly patients with NSCLC and other thoracic cancers, the optimization of first- and second-line treatment for patients with small cell lung cancer, and the selection of chemotherapy or immunotherapy for patients with mesothelioma and thymic neoplasms. We will also address areas of ongoing research including immune toxicities and attempts to overcome resistance to ICI.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us